Genital Neoplasms, Female  >>  Lynparza (olaparib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lynparza (olaparib) / Merck (MSD), AstraZeneca
NCT00494442 / 2006-006459-10: Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Completed
2
58
US, Europe, RoW
KU-0059436 (AZD2281)(PARP inhibitor), Olaparib
AstraZeneca, KuDOS Pharmaceuticals Limited
Ovarian Neoplasm
03/09
07/17
NCT01661868 / 2013-003088-76: Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Withdrawn
2
0
US
Olaparib, AZD2281
Dana-Farber Cancer Institute
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
08/12
08/12
NCT02340611: A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Completed
2
4
Canada
Olaparib, AZD2281, KU-0059436, Cediranib, AZD2171, Recentin™
University Health Network, Toronto, AstraZeneca
Ovarian Cancer
06/18
06/18

Download Options